解剖可切除胰腺癌 upfront 切除的无效性标准
本研究基于意大利5个高容量中心的1426例连续接受upfront胰十二指肠切除术的患者,开发了预测无效性切除(术后6个月内死亡或复发)的风险模型MetroPancreas,并提出了使无效性风险低于20%的CA19.9-肿瘤大小标准。无效性切除率为18.9%,满足标准者无病生存和总生存显著更长。
要点
- 无效性切除定义为术后6个月内死亡或复发,本队列发生率为18.9%。
- 术前与无效切除相关的变量包括ASA分级、CA19.9水平和肿瘤大小。
- 四项CA19.9调整肿瘤大小标准与无效性风险低于20%相关。
核心结论
- 开发了术前模型MetroPancreas及二分标准,用于预测解剖可切除胰腺癌upfront切除的无效性风险。
- 该模型可能有助于选择患者接受upfront切除或新辅助治疗。
研究设计与样本
- 样本分为 derivation 队列(n=885)和 validation 队列(n=541)。
主要发现
- 无效性胰切除率为18.9%(derivation队列19.2%,validation队列18.6%)。
- 术前与无效切除相关的变量包括ASA分级(系数95%CI 0.68-0.87)、CA19.9血清水平(系数95%CI 0.05-0.75)和肿瘤大小(系数95%CI 0.28-0.46)。
- 识别出三个风险组,其无效切除可能性递增、病理特征更差且结局更差。
- 符合四项标准中任一项的患者,其无病生存和总生存均显著更长。
关键数值与推荐
- 肿瘤大小<2 cm且CA19.9<1000 U/mL;肿瘤大小<3 cm且CA19.9<500 U/mL;肿瘤大小<4 cm且CA19.9<150 U/mL;肿瘤大小<5 cm且CA19.9<50 U/mL。
- 上述四项条件均与无效性可能性低于20%相关。
临床怎么用
- 对于解剖可切除胰腺癌患者,可依据MetroPancreas模型及CA19.9-肿瘤大小标准评估无效性切除风险。
- 符合标准者无效性风险低于20%,可考虑upfront切除;不符合者可能从新辅助治疗中获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: There are currently no clinically relevant criteria to predict a futile up-front pancreatectomy in patients with anatomically resectable pancreatic ductal adenocarcinoma. OBJECTIVES: To develop a futility risk model using a multi-institutional database and provide unified criteria associated with a futility likelihood below a safety threshold of 20%. DESIGN, SETTING, AND PARTICIPANTS: This retrospective study took place from January 2010 through December 2021 at 5 high- or very high-volume centers in Italy. Data were analyzed during April 2024. Participants included consecutive patients undergoing up-front pancreatectomy at the participating institutions. EXPOSURE: Standard management, per existing guidelines. MAIN OUTCOMES AND MEASURES: The main outcome measure was the rate of futile pancreatectomy, defined as an operation resulting in patient death or disease recurrence within 6 months. Dichotomous criteria were constructed to maintain the futility likelihood below 20%, corresponding to the chance of not receiving postneoadjuvant resection from existing pooled data. RESULTS: This study included 1426 patients. The median age was 69 (interquartile range, 62-75) years, 759 patients were male (53.2%), and 1076 had head cancer (75.4%). The rate of adjuvant treatment receipt was 73.7%. For the model construction, the study sample was split into a derivation (n = 885) and a validation cohort (n = 541). The rate of futile pancreatectomy was 18.9% (19.2% in the development and 18.6% in the validation cohort). Preoperative variables associated with futile resection were American Society of Anesthesiologists class (95% CI for coefficients, 0.68-0.87), cancer antigen (CA) 19.9 serum levels (95% CI, for coefficients 0.05-0.75), and tumor size (95% CI for coefficients, 0.28-0.46). Three risk groups associated with an escalating likelihood of futile resection, worse pathological features, and worse outcomes were identified. Four discrete conditions (defined as CA 19.9 levels-adjusted-to-size criteria: tumor size less than 2 cm with CA 19.9 levels less than 1000 U/mL; tumor size less than 3 cm with CA 19.9 levels less than 500 U/mL; tumor size less than 4 cm with CA 19.9 levels less than 150 U/mL; and tumor size less than 5 cm with CA 19.9 levels less than 50 U/mL) were associated with a futility likelihood below 20%. Both disease-free survival and overall survival were significantly longer in patients fulfilling the criteria. CONCLUSIONS AND RELEVANCE: In this study, a preoperative model (MetroPancreas) and dichotomous criteria to determine the risk of futile pancreatectomy were developed. This might help in selecting patients for up-front resection or neoadjuvant therapy.
引用
- Crippa S, Malleo G, Mazzaferro V, et al. Futility of Up-Front Resection for Anatomically Resectable Pancreatic Cancer. JAMA Surg. 2024. PMID: 39046713. doi:10.1001/jamasurg.2024.2485
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。